MRI
Conditions
Brief summary
Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which two additional sequences of 6 minutes duration will be added. The MRI of routine care includes at least the following sequences: * 3D T1 TFE 1.0 isotropic (2 minutes) * T2 TSE (2 minutes) * 3D FLAIR pre-injection (opt) (3 minutes) * 3D FLAIR post-injection (3 minutes) As part of the research, the following sequences will be acquired: * FABIR pre-injection (3 minutes) * FABIR post-injection (3 minutes) Patients hospitalized for a foreseeable duration of at least 24 hours will be offered participation in the longitudinal tab of the study, for which four non-injected MRI examinations will be performed. The examinations will be carried out remotely from the injected MRI (1h, 2h, 12h-15h, 24h-36h). These exams dedicated to research will include the following sequences for a maximum of 8 minutes: * 3D T1 TFE 1.0 isotropic (2 minutes) * 3D FLAIR (3 minutes) * FABIR (3 minutes)
Interventions
DEVICEMRI with gadolinium injection
Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study. The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5.
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years old * To benefit as part of his treatment of an MRI with injection of gadolinium * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme For the ancillary study to meet secondary endpoint number 5: * Patient over 18 years old * To benefit as part of his treatment of an MRI with injection of gadolinium * Hospitalized for an expected period of at least 48 hours after the time of inclusion * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme
Exclusion criteria
* Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| detection of meningeal contrast enhancement with the flair sequence | 1 DAY |
| detection of meningeal contrast enhancement with the FABIR sequence | 1 day |
Countries
France
Outcome results
None listed